Mylan, Shire Battle Again Over Generic Vyvanse

Law360, New York (February 6, 2012, 5:59 PM EST) -- Mylan Inc. and Johnson Matthey Inc. became the latest targets Thursday of drugmaker Shire LLC's ongoing efforts to protect its patents for the attention deficit hyperactivity disorder treatment Vyvanse.

Shire's New Jersey federal court suit accuses the generic manufacturers of violating 15 patents covering Vyvanse by filing an abbreviated new drug application with the U.S. Food and Drug Administration to produce their own version of the drug.

Shire said in its complaint that the ANDA application for Vyvanse was filed “for the purpose of obtaining approval...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.